MS Briefs

Exclusive breastfeeding lowers the risk of postpartum MS relapse


 

Key clinical point : Most women diagnosed with multiple sclerosis (MS) can have children without incurring an increased risk of relapses and should be encouraged to breastfeed exclusively as this lowers the risk of postpartum relapses.

Major finding : The annualized relapse rates (ARRs) declined from 0.37 before pregnancy to 0.14 during pregnancy ( P less than .0001), with no rebound disease activity in the postpartum period. ARR was found to be 0.27 at 3 months postpartum and 0.37 at 4-6 months, matching prepregnancy rates. Exclusive breastfeeding for at least 2 months after delivery reduced the risk of relapse in the first 6 months postpartum (adjusted hazard ratio, 0.37; P = .0093).

Study details : This study evaluated the electronic health records of 466 pregnancies among 375 women with MS and their infants at the Kaiser Permanente Southern and Northern California between 2008 and 2016.

Disclosures: This study was supported by the National Multiple Sclerosis Society. Annette Langer-Gould has received grant support and awards from the NIH, the Patient-Centered Outcomes Research Institute, and the National MS Society; and currently serves as a voting member on the California Technology Assessment Forum, a core program of the Institute for Clinical and Economic Review (ICER). She has received sponsored and reimbursed travel from the ICER. The remaining authors declared no conflict of interest.

Citation: Langer-Gould A et al. Neurology. 2020 Apr 13. doi: 10.1212/WNL.0000000000009374.

Recommended Reading

Cognitive reserve may play protective role in MS-related cognitive dysfunction
ICYMI Multiple Sclerosis
FDA removes pregnancy category C warning from certain MS medications
ICYMI Multiple Sclerosis
Database will collect data on COVID-19 in patients with MS
ICYMI Multiple Sclerosis
Report details first case of PML with ocrelizumab alone
ICYMI Multiple Sclerosis
Five-year siponimod data support early MS treatment
ICYMI Multiple Sclerosis
Cautionary findings on acquired immunodeficiency from anti-CD20 MS therapy
ICYMI Multiple Sclerosis
Initial high-efficacy MS therapy tied to less disability later
ICYMI Multiple Sclerosis
Serum NfL in early MS can help predict clinical course
ICYMI Multiple Sclerosis
Natalizumab bests fingolimod for relapsing-remitting MS
ICYMI Multiple Sclerosis
Neurologists’ pay gets a boost, most happy with career choice
ICYMI Multiple Sclerosis